Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 7/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.37 |
| ▸ | HIPK3 | Q9H422 | 2/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL27801352 | 0.95 | AKT2 (0.53) | AKT2AKT1ILKMAPK1ROCK2 | |
| SCHEMBL610112 | 0.76 | ALDH1A1 (0.33) | — | |
| SCHEMBL197153 | 0.75 | AKT2 (0.61) | AKT2AKT1ILKMAPK1ROCK2 | |
| Benzene SCHEMBL28198087 | 0.74 | AKT2 (1.00) | AKT2AKT1ILKROCK2CHEK1 | |
| SCHEMBL82741 | 0.74 | AKT2 (1.00) | AKT2AKT1ILKROCK2CHEK1 | |
| SCHEMBL3740850 | 0.73 | AKT2 (0.70) | AKT2AKT1ILKMAPK1ROCK2 | |
| SCHEMBL3598468 | 0.73 | METAP2 (0.62) | IDO1METAP2KEAP1 | |
| SCHEMBL30424015 | 0.73 | AKT2 (0.71) | AKT2AKT1ILKROCK2CHEK1 | |
| SCHEMBL16872766 | 0.73 | AKT2 (0.95) | AKT2AKT1ILKROCK2CHEK1 | |
| Hydrochloric Acid SCHEMBL72435 | 0.73 | AKT2 (0.95) | AKT2AKT1ILKROCK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022266248-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| US-20100261761-A1 | Novel Sulfonylpyrroles | MAIER THOMAS | 2010-10-14 | — | — | US | claimed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| CN-101801963-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | claimed |
| EP-2176256-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | claimed |
| CN-101137623-A | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | NYCOMED GMBH (DE) | 2008-03-05 | — | — | CN | claimed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| CN-1926103-A | Sulfonyl pyrroles as HDAC inhibitors | ALTANA PHARMA AG (DE) | 2007-03-07 | — | — | CN | claimed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | AKT2 813/4885AKT1 810/4885ILK 1960/4885 |
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | AKT2 2742/4885AKT1 3430/4885ILK 4644/4885 |
| US-20100261761-A1 | Novel Sulfonylpyrroles | HDAC3, HDAC1, HDAC2 | AKT2 1745/4885AKT1 1847/4885ILK 4340/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | AKT2 943/4885AKT1 840/4885ILK 1197/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | AKT2 943/4885AKT1 840/4885ILK 1197/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | AKT2 843/4885AKT1 857/4885ILK 1938/4885 |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | AKT2 10/4885AKT1 25/4885ILK 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.